We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » INGREDIENT CONCERNS INVALIDATE TENTATIVE APPROVAL
INGREDIENT CONCERNS INVALIDATE TENTATIVE APPROVAL
January 16, 2004
Concerns about raw material used to make a generic version of Bristol-Myers Squibb’s diabetes drug Glucophage XR have prompted the FDA to withdraw the tentative approval it gave to Barr Pharmaceuticals, the firm said Jan. 9.